First shot at a $SGMO collaboration cash inflow analysis.  Still too much guess work until some milestones are triggered from #oncology and #CNS deals.  
#GeneTherapy $BIIB $GILD $PFE $TAK $SNY https://t.co/LZDGimsn8Q